Soon afterward, several degraders entered clinical trials: ARV-766 (Arvinas) and AR-LDD (Bristol Myers Squibb) targeting AR for prostate cancer; DT2216 (Dialectic) targeting BCL-XL for liquid and solid cancers; KT-413 (Kymera) targeting IRAK4 for diffuse large B cell lymphoma (DLBCL); KT-333 (Kymera) targeting STAT3 for liquid and solid cancers; NX-2127 and NX-5948 (Nurix) targeting BTK for B cell malignancies; CG001419 (Cullgen) targeting tropomyosin receptor kinase (TRK) for cancer; CFT8634 (C4 Therapeutics) and FHD-609 (Foghorn) targeting BRD9 for synovial sarcoma. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.